Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (2134)
  2. Journal Article (1755)
  3. Review (262)
  4. Editorial (133)
  5. Research Letter (85)
  6. Correspondence (45)
  7. Book Section (31)
  8. Guidelines (25)
  9. Miscellaneous (13)
  10. Conference Paper (8)
Groups
  1. Department of Medicine (4172)
  2. Weinberg Fellows (2756)
  3. Hematologic Malignancies, Division of (2492)
  4. Solid Tumor Oncology Division (2422)
  5. Center for Hematologic Malignancies (1945)
  6. GSK Faculty (1879)

More Groups

People
  1. Sergio Giralt (433)
  2. Michael Scordo (389)
  3. Gunjan Shah (348)
  4. Miguel-Angel Perales (338)
  5. Sean Devlin (289)
  6. Marcel Van Den Brink (263)

More People

Years
  1. 2025 (343)
  2. 2024 (636)
  3. 2023 (600)
  4. 2022 (628)
  5. 2021 (503)
  6. 2020 (496)

More Years

Publications
  1. Blood (713)
  2. Journal of Clinical Oncology (685)
  3. Annals of Oncology (133)
  4. Clinical Cancer Research (131)
  5. Cancer Research (126)
  6. Biology of Blood and Marrow Transplantation (124)

More Publications

Publishers
  1. American Society of Hematology (806)
  2. American Society of Clinical Oncology (774)
  3. Elsevier Inc. (544)
  4. Nature Publishing Group (358)
  5. American Association for Cancer Research (352)
  6. Oxford University Press (211)

More Publishers

Results (4491)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2-advanced breast cancer: ReDiscover trial
    Meeting Abstract

    Sammons, S. L.; Manich, C. S.; Italiano, A.; Schram, A. M.; Ortega, P. T.; Schott, A. F.; Guerrero, A.; Aix, S. P.; Nanda, R.; Wisinski, K. B.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns in HR+/HER2-metastatic breast cancer (MBC) with co-occurring PIK3CA and ESR1 mutations
    Meeting Abstract

    Teysir, J.; Shen, S.; White, C.; Chen, Y.; Razavi, P.; Jhaveri, K. L.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Ultrasensitive ctDNA monitoring during CDK4/6 inhibitor therapy for metastatic breast cancer
    Meeting Abstract

    Ah-Reum An, J.; Jasper, J.; Cabel, L.; Yildirim, S. Y.; da Silva, E. M.; Patel, R. K.; LaBella, M.; Teysir, J.; Mai, N.; Safonov, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Pilot study of an enhanced telehealth program for patients with prostate cancer
    Meeting Abstract

    Bange, E. M.; Reiner, A. S.; Liebertz, C.; Chimonas, S.; Daly, R. M.; Malling, C.; Lei, S.; Campbell, R.; Stevanovic, K.; Holland, J. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Circulating tumor DNA (ctDNA) dynamics as a predictor of treatment response in metastatic breast cancer (mBC)
    Meeting Abstract

    Razavi, P.; Cabel, L.; Teysir, J.; An, J. A. R.; Rivero-Hinojosa, S.; Satta, S.; Bristow, S. L.; Kalashnikova, E.; Rodriguez, A. A.; Liu, M. C.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Opportunities for home cancer care: The final frontier
    Editorial

    Doshi, S. D.; Malling, C. D.; McNiff Landrum, K.; Zachariah, F.; Bange, E. M.; Daly, B.
    NEJM Catalyst Innovations in Care Delivery (2025)

    Fulltext@MSK | Save
  • Beamion PANTUMOR-1: A phase II, multicenter, multicohort, open-label trial to evaluate the efficacy and safety of the oral HER2-selective tyrosine kinase inhibitor zongertinib for the treatment of HER2 -mutated or overexpressed/amplified solid tumors
    Meeting Abstract

    Schram, A. M.; Clay, T. D.; Prenen, H.; Park, J. J.; Lunger, L.; Hussain, J.; Maier, D.; Kitano, S.; Dumbrava, E. E.; Kim, H. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Wang, P.; Ellis, J.; Bar, M.; Kumar, J.; Farazi, T. A.; Garcia-Sancho, A. M.; Izutsu, K.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of MTAP deletion on immunotherapy outcomes in patients with mesothelioma
    Meeting Abstract

    Ross, J.; Ortiz, E.; Barraza, G.; Mayoral, M.; Ginsberg, M. S.; Luongo, A.; Arfe, A.; Zauderer, M. G.; Adusumilli, P. S.; Eckert, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save